Please provide your email address to receive an email when new articles are posted on . The approval applies to certain patients with myasthenia gravis or chronic inflammatory demyelinating ...
The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized ...
Previously, the treatment had only been supplied in a single-dose vial that required administration by a health care professional using a winged infusion set. The Food and Drug Administration (FDA) ...
The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
(RTTNews) - argenx SE (ARGX) said that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application or sBLA for VYVGART Hytrulo (efgartigimod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results